Telephus gets patents for superbug battling antibodies

By Gareth Macdonald

- Last updated on GMT

Telephus gets patents for superbug battling antibodies

Related tags Monoclonal antibody

Australia has granted Telephus Medical a patent for an antibody that targets superbugs, including MRSA.

The patent covers the science that underpins its methicillin-resistant Staphylococcus aureus (MRSA) targeting monoclonal antibody, TPH 101.

The monoclonal antibody is designed to both treat and prevent infection by binding the endo-β-N-acetylglucosaminidase (Gmd) subunit of staphylococcal autolysin, which is the enzyme that allows Staphylococci ​to attach to tissues and form biofilms.

In animal studies the antibody was shown to accelerate bacterial clearance and inhibit bacterial growth.

California, US-based Telephus licensed the antibody from a laboratory at New York’s University of Rochester (UR) run by company founder and chief scientific officer (CSO), Edward Schwarz.

Telephus – which is named after an ancient Greek warrior whose wounds only healed thanks to Odysseus’s medical intervention – licensed intellectual property (IP) covering wider therapeutic use of neutralizing antibodies to treat infection.

The Australian patent follow a few weeks after authorities in Canada and Japan issued Telephus with patents for the same antibody.

CEO Mark Benedyk said: “This third patent in our intellectual property estate extends Telephus’ portfolio covering monoclonal antibody compositions and methods targeting antibiotic-resistant bacteria.

He added that: “It also describes the technology on which our initial product, TPH 101, is based.”

In 2013, San Diego-headquartered Telephus told Xconomy it had raised $1.4m from individual investors and the Wilson Sonsini law firm and said it planned to take the drug into Phase I trials in 2016​.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Follow us